Patents by Inventor Robert Gordon Giles

Robert Gordon Giles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7358366
    Abstract: A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the “Polymorph”) characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm?1; and/or (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm?1; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0, and 175.0 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: April 15, 2008
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Paul David James Blackler, Robert Gordon Giles, Stephen Moore, Michael John Sasse
  • Patent number: 7351832
    Abstract: A process for preparing a compound of formula (I): or a tautomeric form thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A1 represents a substituted or unsubstituted aromatic heterocyclyl group; R1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; A2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6, which process comprises catalytically reducing a compound of formula (II): wherein A1, R1, A2 and n are as defined in relation to formula (I), characterised in that the reduction reaction is carried out using a hydrogen pressure above 20 psi; and thereafter if required forming a pharmaceutically acceptable salt and/or a pharmaceutically acceptable solvate of the compound of formula (I).
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: April 1, 2008
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Robert Gordon Giles, Norman John Lewis, John Kirby Quick
  • Patent number: 7091359
    Abstract: A process for preparing a compound of formula (I) or a tautomeric form thereof or a pharmaceutically acceptable salt thereof, wherein: A1 represents a substituted or unsubstituted aromatic heterocyclyl group; R1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; A2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6, which process comprises catalytically reducing a compound of formula (II): wherein A1, R1, A2 and n are as defined in relation to formula (I), characterized in that the reduction reaction is carried out using a hydrogen pressure above 20 psi; and thereafter if required forming a pharmaceutically acceptable salt and/or a pharmaceutically acceptable solvate of the compound of formula (I).
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: August 15, 2006
    Assignee: SmithKline Beecham plc
    Inventors: Robert Gordon Giles, Norman John Lewis, John Kirby Quick
  • Publication number: 20040248945
    Abstract: A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the “Polymorph”) characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm−1; and/or (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm−1; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0, and 175.0 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
    Type: Application
    Filed: May 12, 2004
    Publication date: December 9, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Paul David James Blackler, Robert Gordon Giles, Stephen Moore, Michael John Sasse
  • Patent number: 6815457
    Abstract: A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]-benzyl]thiazolidine-2,4-dione, maleic acid salt (the “Polymorph”) characterized in that it: (i) provides an infra red spectrum containing peaks at 1360, 1326, 1241, 714 and 669 cm−1; and/or (ii) provides a Raman spectrum containing peaks at 1581, 768, 670, 271 and 226 cm−1; and/or (iii) provides a solid-state nuclear magnetic resonance spectrum containing peaks at chemical shifts substantially as set out in Table I; and/or (iv) provides an X-ray powder diffraction (XRPD) pattern containing peaks substantially as set out in Table II; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: November 9, 2004
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Paul David James Blackler, Robert Gordon Giles, Michael Sasse
  • Patent number: 6806280
    Abstract: A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]-thiazolidine-2, 4-dione, maleic acid salt (the “Polymorph”) characterized in that it provides: (i) an infra red spectrum containing peaks at 1763, 912, 856 and 709 cm−1; and/or (ii) a Raman spectrum containing peaks at 1762, 1284, 912 and 888 cm−1; and/or (iii) a solid-state 13C nuclear magnetic resonance spectrum containing peaks at 111.0, 113.6, 119.8, 129.1, 130.9, 131.8, 134.7, 146.5, 152.7, 157.5, 169.5, 171.0, 178.7 ppm; and/or (v) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings at 5.87, 5.30, 4.69, 4.09, 3.88, 3.61, 3.53 and 3.46 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
    Type: Grant
    Filed: December 3, 2001
    Date of Patent: October 19, 2004
    Assignees: SmithKline Beecham p.l.c., SmithKline Beecham (Cork) Limited
    Inventors: Paul David James Blackler, Christine Marie Browne, Timothy G. Coakley, Robert Gordon Giles, Gillian Morrissey
  • Publication number: 20040092555
    Abstract: A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the “Polymorph”) characterised in that it: (i) provides an infra red spectrum containing peaks at 1360, 1326, 1241, 714 and 669 cm−1; and/or (ii) provides a Raman spectrum containing peaks at 1581, 768, 670, 271 and 226 cm−1; and/or (iii) provides a solid-state nuclear magnetic resonance spectrum containing peaks at chemical shifts substantially as set out in Table I; and/or (iv) provides an X-ray powder diffraction (XRPD) pattern containing peaks substantially as set out in Table II; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
    Type: Application
    Filed: November 7, 2003
    Publication date: May 13, 2004
    Applicant: SmithKline Beecham pIc
    Inventors: Paul David James Blackler, Robert Gordon Giles, Michael John Sasse
  • Patent number: 6632947
    Abstract: A process for preparing a compound of formula (I, I) or a tautomeric form thereof or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, wherein: J represents O or S; T represents a substituted or unsubstituted aryl group and T1 is O or S; which process comprises reducing a compound of formula (II, II) or a tautomeric form thereof or a salt thereof or a solvate thereof, wherein T and T1 are as defined in relation to formula (I), with a complex hydride reducing agent or a source of a complex hydride reducing agent; and thereafter, as required, preparing a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate of the compound of formula (I) or a tautomeric form thereof.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: October 14, 2003
    Assignee: SmithKline Beecham plc
    Inventors: Robert Gordon Giles, Norman John Lewis, Stephen Moore, Colin Ripley Pool, John Kirby Quick, Michael Urquhart
  • Publication number: 20030092742
    Abstract: A process for preparing a compound of formula (I) or a tautomeric form thereof or a pharmaceutically acceptable salt thereof, wherein: A1 represents a substituted or unsubstituted aromatic heterocyclyl group; R1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; A2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6, which process comprises catalytically reducing a compound of formula (II): wherein A1, R1, A2 and n are as defined in relation to formula (I), characterized in that the reduction reaction is carried out using a hydrogen pressure above 20 psi; and thereafter if required forming a pharmaceutically acceptable salt and/or a pharmaceutically acceptable solvate of the compound of formula (I).
    Type: Application
    Filed: November 4, 2002
    Publication date: May 15, 2003
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Robert Gordon Giles, Norman John Lewis, Jonh Kirby Quick
  • Publication number: 20020120150
    Abstract: 1
    Type: Application
    Filed: February 26, 2002
    Publication date: August 29, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Robert Gordon Giles, Norman John Lewis, John Kirby Quick
  • Publication number: 20020042519
    Abstract: A process for preparing a compound of formula (I, I) or a tautomeric form thereof or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, wherein: J represents O or S; T represents a substituted or unsubstituted aryl group and T1 is O or S; which process comprises reducing a compound of formula (II, II) or a tautomeric form thereof or a salt thereof or a solvate thereof, wherein T and T1 are as defined in relation to formula (I), with a complex hydride reducing agent or a source of a complex hydride reducing agent; and thereafter, as required, preparing a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate of the compound of formula (I) or a tautomeric form thereof.
    Type: Application
    Filed: November 8, 2001
    Publication date: April 11, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Robert Gordon Giles, Norman John Lewis, Stephen Moore, Colin Ripley Pool, John Kirby Quick, Michael Urquhart
  • Patent number: 6069257
    Abstract: A process for preparing certain substituted benzopyran compounds of formula (I) ##STR1## is disclosed.
    Type: Grant
    Filed: July 6, 1999
    Date of Patent: May 30, 2000
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Robert Gordon Giles, Norman John Lewis, Paul Oxley, John Kirby Quick
  • Patent number: 6048983
    Abstract: A process for preparing certain substituted benzopyran compounds is disclosed.
    Type: Grant
    Filed: February 8, 1999
    Date of Patent: April 11, 2000
    Assignee: SmithKline Beecham pl.c
    Inventors: Robert Gordon Giles, Paul Oxley